Furmonertinib Tablets

Furmonertinib (brand name Alflutinib in China) is a third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) used for EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC), including EGFR T790M-mutated disease (approved indication in China) and under active investigation for EGFR exon 20 insertion-positive NSCLC in the US.

Furmonertinib selectively inhibits mutant forms of the EGFR protein (including T790M resistance mutations and exon 20 insertions) that drive tumor growth in certain NSCLC cases, while sparing wild-type EGFR, and has shown good penetration into the central nervous system.

• As with other EGFR-TKIs, interstitial lung disease/pneumonitis is a possible risk requiring monitoring.
• Liver function abnormalities have been reported.
• QT interval prolongation is a class consideration for EGFR-TKIs.
• Common side effects: diarrhea, rash, elevated liver enzymes, decreased appetite, anemia.

What documents are required to import Furmonertinib to India?

Furmonertinib may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered oncologist specifying dose
• EGFR mutation test report confirming eligibility
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is Furmonertinib available in India?

Furmonertinib is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP), sourced from its approved markets.

Indian Pharma Network (IPN) can source Furmonertinib through authorized international distribution channels and facilitate supply to patients, doctors, and hospitals, subject to sourcing-country export rules.

For Furmonertinib cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• China: Approved by the NMPA — March 2021 (EGFR T790M-mutated NSCLC).
• United States: FDA Breakthrough Therapy Designation granted for EGFR exon 20 insertion-positive NSCLC; not yet fully FDA-approved — verify current status.

What is Furmonertinib used for?

It is a third-generation EGFR-TKI used for EGFR-mutated non-small cell lung cancer, including T790M-mutated disease.

Is Furmonertinib FDA approved?

Not yet in the US — it is approved in China and holds FDA Breakthrough Therapy Designation for a specific NSCLC subtype in the US. Verify current status before treatment decisions.

Do I need EGFR testing before starting Furmonertinib?

Yes — an EGFR mutation test report confirming eligibility is required.

How much does Furmonertinib cost in India?

Cost depends on sourcing country, dose, and logistics — share your prescription with IPN for a quote.